Completed PHASE2 INTERVENTIONAL 7-arm NCT00641732

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

Sponsor: Takeda

Conditions Venous Thromboembolism

Interventions Enoxaparin TAK-442

Updated 8 times since 2017 Last updated: Mar 13, 2016 Started: Oct 31, 2007 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00641732, this PHASE2 trial focuses on Venous Thromboembolism and remains completed. Sponsored by Takeda, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ajax, Canada , Altoona, United States , Atlanta, United States , Aurora, United States , Bakersfield, United States , Bay Pines, United States , Birmingham, United States , Boise, United States , Burlington, Canada , Cambridge, Canada and 54 more locations